Last reviewed · How we verify
NCT05052554: Fuchs Focus
Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3
Phase 1 trial testing QR-504a in Fuchs Endothelial Corneal Dystrophy. Withdrawn.
12 April 2022
Quick facts
| Lead sponsor | ProQR Therapeutics |
|---|---|
| Phase | Phase 1 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Start date | 10 August 2021 |
| Primary completion | 12 April 2022 |
| Estimated completion | 12 April 2022 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- QR-504a — full drug profile →
Conditions studied
- Fuchs Endothelial Corneal Dystrophy — all drugs for Fuchs Endothelial Corneal Dystrophy →
- FECD3 — all drugs for FECD3 →
- Corneal Diseases — all drugs for Corneal Diseases →
- LRS — all drugs for LRS →
Sponsor
ProQR Therapeutics — full company profile →
Who can join
18 and older, any sex, with Fuchs Endothelial Corneal Dystrophy or FECD3. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
PQ-504a-001 (Fuchs Focus) is an open-label, single-dose, exploratory study to evaluate safety, tolerability, and corneal endothelium molecular biomarker(s) in subjects with Fuchs Endothelial Corneal Dystrophy with Trinucleotide Repeat Expansion in the TCF4 gene (FECD3).
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
The Progress and Promise of RNA Medicine─An Arsenal of Targeted Treatments.
Sasso JM, Ambrose BJB, Tenchov R, Datta RS, et al · · 2022 · cited 69× · PMID 35533054 · DOI 10.1021/acs.jmedchem.2c00024 -
Therapeutic future of Fuchs endothelial corneal dystrophy: An ongoing way to explore.
Liu JX, Chiang TL, Hung KF, Sun YC. · · 2024 · cited 5× · PMID 38654984 · DOI 10.4103/tjo.tjo-d-23-00115
Verify or expand the search:
- PubMed search for NCT05052554
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Fuchs Endothelial Corneal Dystrophy
Currently open trials in the same condition.
- NCT04440280 — Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy · Phase 2 · recruiting
Other ProQR Therapeutics trials
Trials by the same sponsor.
- NCT04123626 — A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due · Phase 1, PHASE2 · active not recruiting
- NCT03780257 — Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05052554 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ProQR Therapeutics
- Last refreshed: 11 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05052554.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing